StockData

BioCryst Pharmaceuticals vs Moderna

BCRX and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCRX and MRNA compare

Moderna is the larger company, worth 43 times as much as BioCryst Pharmaceuticals ($82.6B against $1.9B).

BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus −27.6% for Moderna).

BioCryst Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −40.9% compared with −141% at Moderna.

BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCRXMRNA
Size and price
Market cap$1.9B$82.6B
Share price$7.50$206.80
Change, 1 year5.9%735%
Change, 5 years−39.9%−37.3%
Beta (5Y)0.58−0.29
Employees4354,700
StockData Score
Total score9 (better)5
Valuation score1 (better)0
Growth score4 (better)1
Performance score2 (better)1
Health score23 (better)
Dividend score00
Valuation
P/S2.0× (better)37.1×
P/B–12.2×
P/FCF5.1×–
FCF yield19.5% (better)−1.5%
Fair value–$32.48
Margin of safety–−537%
Growth
Revenue growth (TTM)68.7% (better)−27.6%
Revenue growth, 5Y average118% (better)19.3%
Profitability
Gross margin97.8% (better)23.4%
Operating margin−33.3% (better)−149%
Net margin−40.9% (better)−141%
FCF margin39.7% (better)−55.8%
Return on equity–−39.0%
Return on invested capital–−80.9%
Financial health
Debt / equity–0.09
Interest coverage−4.2×–
Current ratio2.32 (better)2.29
Altman Z-score−3.8312.01 (better)
Piotroski F-score7 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions103%79.9%
Held by insiders1.9%5.6%
Insider net buying, 12 months−$4.1M (better)−$81.6M
Short interest, % of float11.0%8.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.